Seres醫療 MCRB 深 滬
等待開盤 10-16 09:30:00 美东时间
19.70
0.000
0.00%
華盛通- 最 高20.85
- 今 開19.699
- 成交量 10.88万股
- 最 低 19.17
- 昨 收 19.70
- 總市值 1.72亿
- 52周最高 24.6651
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 6.53
- 委 比 13.42%
- 總股本 875.46万
- 歷史最高 1040.00
- 量 比 1.11
- 振 幅 8.53%
- 歷史最低 7.20
- 每 手 1
- 風險率 3.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Seres Therapeutics to present Phase 1b data on SER-155 at IDWeek 2025, showcasing a 77% reduction in bloodstream infections and improved microbiological outcomes in allo-HSCT patients. The company is planning a Phase 2 study following FDA feedback and seeking partnerships for development.
10-14 11:00
Seres Therapeutics Announces Actions To Reduce Operating Costs; Reducing Workforce By About 25%; Workforce Reduction To Result In Cash Charges Of $1M-$1.4M
On September 23, 2025, Seres Therapeutics, Inc. (the "Company") announced actions to reduce operating costs in order to extend its cash runway to provide additional opportunities to advance its strategic
10-04 04:15
Seres Therapeutics Receives FDA Feedback To Finalize Phase 2 Protocol For SER-155 In Preventing BSIs In Allo-HSCT Patients
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for
09-23 19:06
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Seres Therapeutics received constructive FDA feedback for its SER-155 Phase 2 study protocol to prevent bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. The company is preparing to operationalize the study, pending capital securing, with interim results expected within 12 months. To extend its cash runway into Q2 2026, Seres reduced its workforce by ~25% and implemented cost-saving measures. The study aim...
09-23 11:00
Rapport Therapeutics prices $250M stock at $26 per share
Rapport Therapeutics (NASDAQ:RAPP) priced an underwritten public offering of 9.62M shares at a public offering price of $26.00 per share. The underwriters have a 30-day option to purchase up to an add...
09-10 15:30
TK Elevator's owners are said to prepare for potential 2026 IPO
Private equity groups Advent and Cinven are in talks with banks as they begin laying the groundwork for a public listing of TK Elevator, a move that could rank among Europe’s largest stock market debu...
09-08 22:18
Seres Therapeutics soars on report of takeover offer
Seres Therapeutics jumped 21% in premarket trading after a report that Nestle made a takeover offer of ~$760 million for the company. The $41 a share all-cash offer was valid until the end of August,...
09-08 21:04
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Shares of Robinhood Markets, Inc. (NASDAQ:HOOD) rose sharply in pre-market trad...
09-08 17:30
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics announced its management will present at the H.C. Wainwright Global Investment Conference in NYC on September 8. The presentation will cover the company's overview and its pipeline, including SER-155, which has received Breakthrough Therapy and Fast Track designations for reducing infections and graft-versus-host disease in allo-HSCT patients. A webcast replay will be available on the company's website for 21 days after the eve...
08-27 11:00
Seres Therapeutics Reports Q2 Results and Leadership Change
Seres Therapeutics ( ($MCRB) ) has shared an announcement. On August 6, 2025, S...
08-06 19:28
